Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.01, for a total transaction of $5,006,595.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $21,350,756.13. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

Shares of UTHR stock opened at $532.53 on Friday. The firm has a market cap of $23.34 billion, a P/E ratio of 19.09, a P/E/G ratio of 1.95 and a beta of 0.84. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $549.50. The firm has a fifty day moving average of $494.79 and a two-hundred day moving average of $471.76.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the firm earned $6.19 EPS. The company’s revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst support: Several brokerages have raised targets or reiterated buy/outperform views (Oppenheimer, Cantor Fitzgerald, Jefferies cited) which underpins upside expectations. Read More.
• Positive Sentiment: Wells Fargo published a bullish forecast calling for meaningful price appreciation, adding directional support to sentiment. Read More.
• Positive Sentiment: Recent quarterly results: UTHR reported an EPS beat (EPS above consensus) and revenue growth, which has prompted analyst upward revisions and helps the fundamental story. Read More.
• Neutral Sentiment: Consensus remains a “Moderate Buy” — constructive but not unanimous, keeping expectations elevated yet measured. Read More.
• Neutral Sentiment: Institutional ownership is high (~94% reported), which typically supports liquidity but can limit float-driven volatility. Read More.
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in late March; director Tommy Thompson also trimmed his stake — large officer sales are weighing on sentiment and likely contributed to the stock pullback. CEO sale filing: Read More.; CFO filing: Read More.; coverage: Read More. and Read More.
• Neutral Sentiment: Short-interest data is unclear in recent feeds and does not currently indicate a clear short-squeeze or bearish pressure. Read More.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC increased its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. raised its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wells Fargo & Company upped their price objective on United Therapeutics from $466.00 to $486.00 and gave the company an “equal weight” rating in a research note on Monday. Royal Bank Of Canada upped their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. HC Wainwright boosted their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $549.91.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.